

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 September 2024 (12.09.2024)



(10) International Publication Number
WO 2024/184146 A1

- (51) International Patent Classification:
A61K 31/5415 (2006.01) *A61P 25/28* (2006.01)
- (21) International Application Number:
PCT/EP2024/055065
- (22) International Filing Date:
28 February 2024 (28.02.2024)

- (25) Filing Language: English
- (26) Publication Language: English

- (30) Priority Data:
202311014304 03 March 2023 (03.03.2023) IN

- (71) Applicant: **WISTA LABORATORIES LTD.** [SG/SG];
25 Bukit Batok Crescent, The Elitist #06-13, Singapore
658066 (SG).

- (72) Inventor; and
(71) Applicant (for MG only): **WISCHIK, Claude Michel**
[GB/GB]; TauRx Therapeutics Ltd., 395 King Street, Ab-
erdeen Aberdeenshire AB24 5RP (GB).

- (72) Inventors: **TRIPATHI, Shailendra Mohan**; 3/165, Vi-
jayant Khand, Gomti Nagar, Lucknow 226010 (IN). **MUR-
RAY, Alison Dorothy**; Mill of Findon, Portlethen Ab-
erdeenshire AB12 4QQ (GB). **STAFF, Roger Todd**; De-
partment of Nuclear Medicine, Aberdeen Royal Infirmary,
Forresterhill, Aberdeen Aberdeenshire AB25 2ZD (GB).
SHIELLS, Helen; TauRx Therapeutics Ltd., 395 King
Street, Aberdeen Aberdeenshire AB24 5RP (GB). **SCHEL-
TER, Bjoern Olaf**; TauRx Therapeutics Ltd., 395 King
Street, Aberdeen Aberdeenshire AB24 5RP (GB).

- (74) Agent: **MEWBURN ELLIS LLP**; Aurora Building, Coun-
terslip, Bristol BS1 6BX (GB).

- (81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

- (84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE



WO 2024/184146 A1

- (54) Title: DIAMINOPHENOTHIAZINE FOR THE TREATMENT OF MICROVASCULAR BRAIN DISEASE DISEASE

(57) Abstract: The invention provides a method of therapeutic or prophylactic treatment of microvascular brain disease in a subject, which method comprises orally administering to said subject reduced form of a methylthioninium (MT)-containing compound, wherein said administration provides a total daily dose of between 8 and 200 mg of MT to the subject per day, optionally split into 2 or more doses.